Login
$ZNTL
$1.63 +$0.03 (1.87%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Julie Eastland Also a director
President, Chief Executive Officer and Director
62 Not stated $1,300,731
Ingmar Bruns
Chief Medical Officer
51 Since 2024
2 years
$869,843
James Bucher
Chief Legal Officer and Corporate Secretary
60 Since 2025
1 year
$659,973

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 30, 2026 · updated by the 8-K of May 27, 2026

Directors
7
serving now
Independent
4 of 5
stated in the proxy; 2 not stated
Average tenure
3.5 years
from year joined
CEO also chairs the board
No
Scott Myers
Director Age On board Independent Committees Other public boards 2025 pay Source
Scott Myers
60 2024
2 years
Independent
Compensation Nominating and Corporate Governance
None stated $184,136
Julie Eastland
62 2024
2 years
Not independent None stated None stated Paid as CEO
David Johnson
61 2020
6 years
Independent
Compensation · Chair
Aura (Nasdaq: AURA) $139,251
Jan Skvarka, Ph.D.
59 2022
4 years
Independent
Audit Nominating and Corporate Governance · Chair
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) $151,405
Enoch Kariuki, Pharm.D.
44 2021
5 years
Not stated None stated None stated $151,405
Luke Walker, M.D.
54 2024
2 years
Independent
Audit Nominating and Corporate Governance
Context Therapeutics Inc. (Nasdaq: CNTX) $145,266
Shannon Campbell Joined May 22, 2026
- - -
Compensation Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

2 disclosed in the proxy filed Apr 30, 2026
Matrix Capital Master Fund, LP
one of our then stockholders owning more than 5% of our outstanding Common Stock
$1.33 per share
December 2025

Company repurchased 7,500,000 shares of its common stock from Matrix at $1.33 per share under a Stock Purchase Agreement

Cam Gallagher
our former President, interim Chief Financial Officer and interim Treasurer and a former member of our Board
Zero dollars
For the years ended December 31, 2024, and December 31, 2025

License agreement under which Zeno Pharmaceuticals, Inc. was granted an exclusive worldwide license; Gallagher is a managing member of and holds an ownership interest in Recurium IP; zero milestone fees paid to Recurium IP

With Recurium IP Holdings, LLC Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support